Becton Dickinson and Co vs 8x8 Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while 8x8 Inc trades at $2.16 (market cap $323.54M). The key difference: Becton Dickinson and Co is far larger — about 151.2× 8x8 Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| BDX | EGHT | |
|---|---|---|
Market Cap | $48.93B | $323.54M |
Sector | Health | Technology |
52-Week High | $185.39 | $2.76 |
52-Week Low | $138.62 | $1.59 |
Enterprise Value | $65.03B | $590.46M |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
EGHT trades at $2.30, up 1.1% today, with a bullish technical signal from moving averages. The company shows strong revenue growth, with five consecutive quarters of year-over-year increases, and has beaten EPS estimates in recent quarters. Recent news highlights the launch of a new partner program and expansion of AI capabilities across its platform. However, the stock carries a high P/E ratio of 74.67, and the company reported a net loss of $27.21 million for 2025.
The outlook is cautiously optimistic, with analyst consensus pointing to significant upside with a $3.13 price target. Key opportunities include sustained revenue growth and AI-driven product expansion, while risks involve high valuation, debt levels, and the challenge of achieving consistent profitability. Institutional sentiment is mixed but leans positive.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →